Topic:

Clinical Trials

Latest Headlines

Latest Headlines

Gilead speeds ahead on idelalisib with promising leukemia data

Gilead may be best known for its HIV drug franchise and a stellar late-stage effort on the hepatitis C front, but the big biotech is also making an ambitious bid to rapidly build a portfolio of cancer drugs. And last night Gilead captured a bit of the ASCO limelight with positive data from a small, early-stage study of the leukemia drug idelalisib (GS-1101).

Roche's next-gen Rituxan candidate impresses in first look at PhIII data

Roche got a big boost for its bid to position the leukemia drug GA101 (obinutuzumab) as a next-gen successor to its blockbuster Rituxan, posting late-stage data last night that showed that a combination with chemotherapy performed much better than chemo alone or in combination with Rituxan.

Quintiles signs on to help Merck KGaA right the R&D ship

Amid repeated pipeline struggles and an R&D re-think, Merck KGaA has signed an exclusive deal with the newly public Quintiles, launching a novel collaboration that will give the CRO a seat at the decisionmaking table.

Quintiles joins Merck KGaA's R&D command post in 5-year exclusive

In the pact, investigators at Merck Serono will join hands with experts at Quintiles to shape and guide the company's R&D strategy while the CRO manages trial planning and execution from Phase I through post-marketing studies.

Biomarker trio enables blood Dx to map heart attack risk

Another team of researchers is tackling the task of developing a blood test designed to predict a patient's likelihood of suffering a heart attack. And they've zeroed on three promising biomarkers to help get the job done.

GlaxoSmithKline's 'independent experts' start to hand out keys to its data vault

Despite a major backlash in the industry, GSK has agreed to open up the data vault to investigators who intend to publish their findings, accelerating a move in the industry to provide greater transparency to the public. But the pharma giant's "independent experts" selected to run the program include at least two people with close ties to GSK.

UPDATED: Baxter adds Gammagard to growing roster of PhIII Alzheimer's failures

The long and frustrating search for something--anything--that can treat Alzheimer's or blunt its symptoms ran into yet another Phase III roadblock this morning as Baxter International reported that its Phase III study of the immune-bolstering treatment Gammagard ended in failure.

Celgene nabs another round of promising pivotal apremalist data for psoriatic arthritis

Celgene has put another brick in the wall of positive late-stage data for apremalist as a new therapy for psoriatic arthritis, building on its new drug application at the FDA.

Bristol-Myers, AstraZeneca report positive data for rare metabolic disease drug

The treatment, under review at the FDA, was acquired by Bristol-Myers Squibb as part of its $5.3 billion acquisition of Amylin last year and swiftly partnered with AstraZeneca in an extension of their 2007 diabetes pact.

CRO Novotech picks up PE investment to expand in Asia

Australia's Novotech has sold off a 30% stake to private equity firm Mercury Capital, planning to use the money to spread its reach across Asia.